Beijing

IN THE global race to use human immune cells to fight cancers, a little-known Chinese firm called GenScript Biotech Corp is emerging as one of the biggest stock gainers.

Among the first Chinese developers of so-called CAR-T cancer therapies, GenScript's shares have risen more than sixfold since June, when it reported positive results from early studies in 35 patients with a type of blood cancer.